Reprise Biomedical: Funding, Investors & Team (Sep 2026)
A Minnesota-based business called Reprise Biomedical, Inc. is committed to commercialising biological medical devices made using a unique perfusion decellularization method that promotes cellular integration. In accordance with a Miromatrix Medical Inc. spin-off, Reprise was established in June 2019. Through the spin-off, Miromatrix transferred to Reprise all acellular medical devices under development as well as two existing FDA 510(k) cleared, commercially accessible medical devices, MiroMesh® Biologic Matrix, and MiroDerm® Biologic Wound Matrix. MiroMesh and MiroDerm are created by decellularizing the highly vascularized pig liver through perfusion. MiroMesh is a surgical matrix that is non-crosslinked and available in a range of sizes for hernia repair applications.
Reprise Biomedical has raised $16.8M across 2 funding rounds on record, the most recent an undisclosed round of $1.5M announced in May 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Reprise Biomedical Company Profile and Key Stats
Latest funding round on record: May 2026.
Reprise Biomedical Funding Rounds
Reprise Biomedical raised $15.3M in an undisclosed round announced in Jan 2023.
3.3 years later, an undisclosed round of $1.5M was announced in May 2026.
Reprise Biomedical Founders and Leadership Team
Contact details for the Reprise Biomedical team: 1 of 1 has an email address on file.
Start 14-day free trial →Reprise Biomedical Funding Compared to Other Biotechnology Startups
Reprise Biomedical's latest round of $1.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Reprise Biomedical in Biotechnology and Plymouth
Companies Similar to Reprise Biomedical
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Reprise Biomedical Funding FAQs
What does Reprise Biomedical do?
A Minnesota-based business called Reprise Biomedical, Inc. is committed to commercialising biological medical devices made using a unique perfusion decellularization method that promotes cellular integration. In accordance with a Miromatrix Medical Inc. spin-off, Reprise was established in June 2019. Through the spin-off, Miromatrix transferred to Reprise all acellular medical devices under development as well as two existing FDA 510(k) cleared, commercially accessible medical devices, MiroMesh® Biologic Matrix, and MiroDerm® Biologic Wound Matrix. MiroMesh and MiroDerm are created by decellularizing the highly vascularized pig liver through perfusion. MiroMesh is a surgical matrix that is non-crosslinked and available in a range of sizes for hernia repair applications.
How much funding has Reprise Biomedical raised?
Reprise Biomedical has raised $16.8M across 2 rounds on record. The most recent is an undisclosed round of $1.5M announced in May 2026.
When did Reprise Biomedical last raise funding?
Reprise Biomedical's most recent funding round on record is an undisclosed round of $1.5M, announced in May 2026.
Who is the CEO of Reprise Biomedical?
Carrie Powers is listed as CEO at Reprise Biomedical.
Where is Reprise Biomedical headquartered?
Reprise Biomedical is based in Plymouth, Minnesota, United States.
How many employees does Reprise Biomedical have?
Reprise Biomedical is in the 11-50 employee band.
How does Reprise Biomedical's funding compare to other Biotechnology startups?
Reprise Biomedical's latest round of $1.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Reprise Biomedical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Reprise Biomedical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.